Multi-omics Decipher the Immune Microenvironment and Unveil Therapeutic Strategies for Postoperative Ovarian Cancer Patients

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Dec 19

PMID 39697734

Authors

Zhibing Liu

Fei Wang

Weiwei Chen

Yujie Zhai

Jinbo Jian

Xiaole Wang

Yingjiang Xu

Jiajia An

Lei Han

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer (OC) is a highly aggressive and often fatal disease that frequently goes undetected until it has already metastasized. The classic treatment for OC involves surgery followed by chemotherapy. However, despite the effectiveness of surgery, relapse is still a common occurrence. Unfortunately, there is currently no ideal predictive model for the progression and drug sensitivity of postoperative OC patients. Cell death patterns play an important role in tumor progression. So we aimed to investigate their potential to be used as indicators of postoperative OC prognosis and drug sensitivity.

Methods: A total of 12 programmed cell death (PCD) patterns were employed to construct novel classification and prognosis model. Bulk transcriptome, genomics, and clinical information were collected from The Cancer Genome Atlas (TCGA) Program-OV, GSE9891, GSE26712, GSE49997 and GSE63885. In addition, single-cell transcriptome data GSE210347 were procured from the Gene Expression Omnibus (GEO) database for subsequent analysis.

Results: In this study, a novel PCD classification has been employed to phenotype postoperative OC patients, revealing that patients in cluster 1 exhibited heightened sensitivity to immune-based therapies combined with high expression of chemokines, interleukins, interferons, and checkpoints. Meanwhile, a programmed cell death index (PCDI) was established using an 8-gene signature with the help of a machine learning algorithm. The patients with high-PCDI had a worse prognosis after surgery in OC. In addition, we also found that patients with low PCDI patients may exhibit sensitivity to immunotherapy, while those with high PCDI patients may display increased responsiveness to tyrosine kinase inhibitors.

Conclusions: This study provides a novel PCD model and nomogram that can effectively predict the clinical prognosis and drug sensitivity of OC patients post-surgery.

References

Fan J, Lee H, Lee S, Ryu D, Lee S, Xue C . Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Genome Res. 2018; 28(8):1217-1227. PMC: 6071640. DOI: 10.1101/gr.228080.117. View

Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E . Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Rep. 2021; 36(3):109412. PMC: 8371260. DOI: 10.1016/j.celrep.2021.109412. View

He Y, Jiang Z, Chen C, Wang X . Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018; 37(1):327. PMC: 6310928. DOI: 10.1186/s13046-018-1002-1. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

Li B, Zhang W, Guo C, Xu H, Li L, Fang M . Benchmarking spatial and single-cell transcriptomics integration methods for transcript distribution prediction and cell type deconvolution. Nat Methods. 2022; 19(6):662-670. DOI: 10.1038/s41592-022-01480-9. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Kent W, Sugnet C, Furey T, Roskin K, Pringle T, Zahler A . The human genome browser at UCSC. Genome Res. 2002; 12(6):996-1006. PMC: 186604. DOI: 10.1101/gr.229102. View

Lu X, Jiang L, Zhang L, Zhu Y, Hu W, Wang J . Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and Clinical Outcome. Neoplasia. 2019; 21(6):591-601. PMC: 6658934. DOI: 10.1016/j.neo.2019.04.003. View

Oehadian A, Koide N, Mu M, Hassan F, Islam S, Yoshida T . Interferon (IFN)-beta induces apoptotic cell death in DHL-4 diffuse large B cell lymphoma cells through tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Lett. 2005; 225(1):85-92. DOI: 10.1016/j.canlet.2004.11.054. View

10.

Liang M, Yang H, Fu J . Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett. 2008; 276(1):47-52. DOI: 10.1016/j.canlet.2008.10.028. View

11.

Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M . Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022; 375(6586):1254-1261. PMC: 9273333. DOI: 10.1126/science.abf0529. View

12.

Zou Y, Xie J, Zheng S, Liu W, Tang Y, Tian W . Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg. 2022; 107:106936. DOI: 10.1016/j.ijsu.2022.106936. View

13.

Aran D, Looney A, Liu L, Wu E, Fong V, Hsu A . Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019; 20(2):163-172. PMC: 6340744. DOI: 10.1038/s41590-018-0276-y. View

14.

Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Buque Martinez A . Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020; 8(1). PMC: 7064135. DOI: 10.1136/jitc-2019-000337. View

15.

Ma G, Zeng S, Zhao Y, Chi J, Wang L, Li Q . Development and validation of a nomogram to predict cancer-specific survival of mucinous epithelial ovarian cancer after cytoreductive surgery. J Ovarian Res. 2023; 16(1):120. PMC: 10294480. DOI: 10.1186/s13048-023-01213-2. View

16.

Jouhault Q, Cherqaoui B, Jobart-Malfait A, Glatigny S, Lauraine M, Hulot A . Interleukin 27 is a novel cytokine with anti-inflammatory effects against spondyloarthritis through the suppression of Th17 responses. Front Immunol. 2023; 13:1072420. PMC: 9933703. DOI: 10.3389/fimmu.2022.1072420. View

17.

Zhou Q, Ding D, Lu M, Zuo M . Multi-Omics Analysis of the Prognostic and Immunological Role of Runt-Related Transcription Factor 3 in Pan-Cancer. Crit Rev Eukaryot Gene Expr. 2023; 33(4):63-83. DOI: 10.1615/CritRevEukaryotGeneExpr.2023044081. View

18.

Tang D, Kang R, Vanden Berghe T, Vandenabeele P, Kroemer G . The molecular machinery of regulated cell death. Cell Res. 2019; 29(5):347-364. PMC: 6796845. DOI: 10.1038/s41422-019-0164-5. View

19.

Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L . Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022; 7(1):286. PMC: 9376115. DOI: 10.1038/s41392-022-01110-y. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View